Xellia Pharmaceuticals, a Copenhagen, Denmark-based pharmaceutical company focused on anti-infective treatments, has completed the expansion of a new $13-million Centralized Laboratory Services building at its manufacturing site in Budapest, Hungary.

The expansion gives the company additional product-stability and release-testing expertise and capabilities.

The new 3,000-square-meters multi-story building accommodates microbiology and chemical analytical laboratories, a product stability center, and administrative offices. It is located next to Xellia’s current active pharmaceutical ingredient (API) manufacturing plant, which employs 250 people.

The new facilities are planned to play a role in Xellia’s global operational strategy to strengthen its product release and stability testing services for APIs and finished dosage forms produced across the company’s other sites in the US, China, and Denmark. The expansion has resulted in the creation of more than 40 new roles within the team with recruitment still ongoing. Xellia is aiming to increase the team at the Centralized Laboratory Services operation to approximately 80 employees by 2019.

Source: Xellia Pharmaceuticals